Clinical trials - Press Releases

Date	Title	Company
22-Jan-2020	Polaryx Therapeutics Receives IND Approval for PLX-200 From the FDA for the Treatment of Late Infantile Neuronal Ceroid Lipofuscinosis	Polaryx Therapeutics, Inc
22-Jan-2020	PredictImmune announces commercial partnership with Cambridge Clinical Laboratories (CCL) to promote and supply PredictSURE IBD™, the world’s first validated prognostic test for inflammatory bowel disease	PredictImmune
22-Jan-2020	Bioprocessing Summit Europe Returns March 24-26, 2020 in Barcelona with New Analytical and Formulation Sessions	Cambridge Healthtech Institute
22-Jan-2020	European Commission Approves Darzalex®▼ (daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone (VTd) for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible	The Janssen Pharmaceutical Companies of Johnson & Johnson
22-Jan-2020	Genmab Announces European Marketing Authorization for DARZALEX® (Daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone in Frontline Multiple Myeloma	Genmab
22-Jan-2020	HepaRegeniX GmbH Secures Series B Financing in Excess of €11 Mio. to Advance First Drug Candidate to the Clinic	HepaRegeniX GmbH
22-Jan-2020	7MM to see sepsis cases grow to 3.1 million by 2026, says GlobalData	GlobalData
22-Jan-2020	IQVIA Named to FORTUNE’s 2020 List of “World’s Most Admired Companies”	IQVIA
22-Jan-2020	Asia-Pacific has a Record Year for Clinical Trials, according to Novotech CRO	Novotech CRO
21-Jan-2020	Exscientia appoints Dr. David Hallett as Chief Operating Officer as company positions for further growth	Exscientia
21-Jan-2020	NORGINE WELCOMES NEW GENERAL MANAGER FOR GERMANY	Norgine B.V.
21-Jan-2020	European Commission Approves Darzalex®▼ (daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone (VTd) for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible	Janssen
21-Jan-2020	SMi’s Pharmaceutical Microbiology in Boston - what to expect over the 2 day conference	SMi Group
20-Jan-2020	Chi-Med Announces that Surufatinib Phase III SANET-p Study Has Already Achieved its Primary Endpoint in Advanced Pancreatic Neuroendocrine Tumors in China and Will Stop Early	Chi-Med
20-Jan-2020	Supporting progress of cell and gene therapy industrialisation with new aseptic manufacturing course	FTI Consulting
20-Jan-2020	Positive update on the development of new XF‐platform drug formulations	Destiny Pharma
20-Jan-2020	V-Bio Ventures invests in RootWave in a EUR 6.5 m Series A financing to develop and market electrical weed killing solutions	V-Bio Ventures
20-Jan-2020	Hart-Scott-Rodino waiting period expires for Sanofi’s acquisition of Synthorx	Sanofi
20-Jan-2020	Unlawful changes to doctors’ pensions scrapped after BMA court victory	The British Medical Association (BMA)
20-Jan-2020	TrakCel appoints Chief Product Officer to accelerate growth	TrakCel